Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
Clin Pharmacokinet ; 45(1): 77-84, 2006.
Article in English | MEDLINE | ID: mdl-16430312

ABSTRACT

BACKGROUND AND OBJECTIVE: The direct thrombin inhibitor ximelagatran, which is rapidly bioconverted to its active form melagatran after oral administration, is being developed for the prevention and treatment of thromboembolism. This study assessed the effects of food and repeated dosing on the pharmacokinetics and pharmacodynamics of melagatran after oral administration of ximelagatran to young healthy Japanese males. METHODS: In part one of the two-part study, volunteers (n = 24) were randomised to receive in a crossover fashion a single oral dose of ximelagatran 48mg with or without breakfast on 2 days separated by a 2- to 7-day washout period. In the second part of the study, all volunteers received oral doses of ximelagatran 48mg every 12 hours for 5 days followed by a single dose on the morning of day 6. RESULTS: The area under the plasma concentration-time curve (AUC), peak plasma concentration (C(max)) and urinary excretion of melagatran did not differ as a function of whether ximelagatran was taken with or without food. The relationship between the melagatran plasma concentration and activated partial thromboplastin time (aPTT, which reflects the thrombin inhibitory effect of melagatran) was also independent of concomitant food intake. During repeated dosing, steady-state plasma concentrations of melagatran were achieved after the second dose of ximelagatran on day 1 and remained stable through the rest of the dosing period. The melagatran AUC and C(max) increased slightly (by 18% and 22%, respectively) on day 6 compared with day 1. The interindividual variability in the melagatran AUC and C(max) remained low, as reflected by coefficients of variation of <20% on both day 1 and day 6. The amount of melagatran excreted in urine remained stable over the 6 days of repeated dosing. CONCLUSION: The pharmacokinetics, pharmacodynamics, safety and tolerability of melagatran after oral administration of ximelagatran were not affected by food or repeated dosing in healthy Japanese volunteers.


Subject(s)
Anticoagulants , Azetidines , Benzylamines , Thrombin/antagonists & inhibitors , Administration, Oral , Adult , Anticoagulants/administration & dosage , Anticoagulants/pharmacokinetics , Anticoagulants/pharmacology , Area Under Curve , Azetidines/administration & dosage , Azetidines/pharmacokinetics , Azetidines/pharmacology , Benzylamines/administration & dosage , Benzylamines/pharmacokinetics , Benzylamines/pharmacology , Cross-Over Studies , Dose-Response Relationship, Drug , Drug Administration Schedule , Food-Drug Interactions , Humans , Japan , Male , Metabolic Clearance Rate
2.
Clin Pharmacokinet ; 45(1): 85-94, 2006.
Article in English | MEDLINE | ID: mdl-16430313

ABSTRACT

OBJECTIVES: Two studies were conducted to elucidate the pharmacokinetics and pharmacodynamics of melagatran after administration of the oral direct thrombin inhibitor ximelagatran to Caucasian and Japanese volunteers. METHODS: In study 1, with a single-blind, parallel-group design, young Japanese and Caucasian male volunteers were randomised to receive four single escalating oral doses of ximelagatran (12, 24, 36 and 60mg on separate days; n = 27 per ethnic group) or placebo (n = 6 per ethnic group). In study 2, with an open-label design, elderly Japanese male volunteers (n = 12) received three single escalating oral doses of ximelagatran (12, 24 and 36mg on separate days). RESULTS: Regardless of the ethnicity or age of the volunteers, ximelagatran given in single oral doses was rapidly absorbed and bioconverted to melagatran, and the melagatran area under the plasma concentration-time curve (AUC) and peak plasma concentration (C(max)) increased in proportion with the ximelagatran dose, with only small deviations from absolute linearity. Higher melagatran AUC and C(max) were observed in young Japanese volunteers compared with young Caucasian volunteers, and in elderly Japanese volunteers compared with young Japanese volunteers. These results appear to be attributed to weight- and age-related decreases in renal elimination of melagatran rather than to absorption of ximelagatran and formation of melagatran. The pattern of metabolites in plasma and urine was comparable between young Japanese and Caucasian volunteers, and between young and elderly Japanese volunteers. The melagatran plasma concentration-activated partial thromboplastin time (aPTT, an ex vivo coagulation time measurement used to demonstrate inhibition of thrombin) relationship did not differ significantly between young Japanese and Caucasian volunteers or between young and elderly Japanese volunteers. CONCLUSIONS: Ethnicity does not affect the absorption of ximelagatran or the formation of melagatran or the melagatran plasma concentration-aPTT relationship. The elimination of melagatran is correlated with renal function.


Subject(s)
Aging , Anticoagulants , Azetidines/administration & dosage , Benzylamines/administration & dosage , Prodrugs/administration & dosage , Thrombin/antagonists & inhibitors , Administration, Oral , Adult , Aged , Aging/ethnology , Aging/metabolism , Anticoagulants/pharmacokinetics , Anticoagulants/pharmacology , Area Under Curve , Asian People , Azetidines/pharmacokinetics , Azetidines/pharmacology , Benzylamines/pharmacokinetics , Benzylamines/pharmacology , Dose-Response Relationship, Drug , Humans , Male , Metabolic Clearance Rate , Single-Blind Method , White People
SELECTION OF CITATIONS
SEARCH DETAIL
...